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Purpose: Several studies have suggested that an HLA-Cw6+ allele can predict an improved 
outcome of treatment in psoriasis patients. The aim of the study was to assess whether the 
published association between HLA-Cw6 allele carriers and response to ustekinumab has the 
potential to impact treatment decisions.
Patients and methods: Differences in Psoriasis Activity and Severity Index 50, 75, and 90; 
Nail Psoriasis Severity Index; and Dermatology Life Quality Index at 16 weeks were evaluated 
between HLA-Cw6 allele carriers vs. non-carriers. Thirty patients with moderate-to-severe 
psoriasis under treatment with ustekinumab were included in our study.
Results: There was no difference between the two groups with respect to Psoriasis Activity 
and Severity Index 50, 75, and 90 or in terms of change in Nail Psoriasis Severity Index or 
Dermatology Life Quality Index.
Conclusion: In our retrospectively analyzed cohort, we could not detect the previously reported 
better response in HLA-Cw6+ vs. HLA-Cw6− patients.
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Introduction
More than 36 genetic loci are associated with psoriasis,1 and of these, HLA-C*06, 
also known as HLA-Cw6 or PSORS1 (6p21.33), has the strongest disease associa-
tion.2–4 HLA-Cw6+ patients tend to have an earlier onset of disease and more severe 
manifestations.5–8 Previous studies have suggested that HLA-Cw6 genotyping could 
possibly play a role in predicting therapy outcome to the interleukin-12/23 antagonist, 
ustekinumab, making pharmacogenomics a promising field of research.9–14
In 2013, Talamonti et al published a cohort study with 51 Caucasian patients, in 
which the treatment response of psoriasis patients under ustekinumab was analyzed 
with respect to three genetic variations: TNFAIP3 rs610604, late cornified envelope 
3B/3C, and HLA-Cw6. While the TNFAIP3 rs610604 polymorphism and the late corni-
fied envelope 3B/3C gene deletions were not found to be associated with statistically 
significant differences in outcome, patients with a polymorphism on the HLA-Cw6 
allele showed increased responses.12
Similar results were observed by Chiu et al in a study of 66 Chinese patients. 
Other clinical variables were analyzed in a multivariate model. However, age, age of 
onset, body weight, Psoriasis Activity and Severity Index (PASI) at baseline, psoriatic 
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arthritis, previous biologics used, and previous traditional 
systemic treatment were not significantly associated with the 
treatment outcome of the interleukin-12/23 blocker, whereas 
the Cw*0602 status was.11
Additionally, the presence of a GG genotype on the IL12B 
rs6887695 single nucleotide polymorphism (SNP) and the 
absence of an AA genotype on the IL12B rs3212227 single-
nucleotide polymorphism have been shown to be associated 
with a superior treatment outcome. This study also confirmed 
previous data on HLA-Cw6, as mentioned above.10
The association was also retrospectively analyzed in 601 
patients, which showed that there is a superior outcome in 
HLA-Cw6+ patients; however, the difference observed in 
this study between the groups was only modest.9
The aim of our study was to determine if there is an 
association between HLA-Cw6 allele carriers and response 
to ustekinumab, retrospectively, in our cohort of patients. 
Our primary endpoint was PASI 75 (a 75% change in PASI) 
at week 16. Secondary outcomes included PASI 50, 90, as 
well as changes in Nail Psoriasis Severity Index (NAPSI) or 
Dermatology Life Quality Index (DLQI) at week 16.
Patients and methods
Patients
Thirty patients with moderate-to-severe psoriasis treated with 
ustekinumab between January 2015 and March 2017 were 
included. Prior authorization for the study was obtained from 
the cantonal ethic commission, Kantonale Ethikkommision 
Zürich, (BASEC-Nr. 2017-00595), and all participants 
needed to sign an informed consent “Einrichtung einer 
dermatologischen Biobank (version 6.0 from 20 February 
2015)”. The patients’ medical data were encrypted, and con-
fidentiality was thus ensured. For all patients, ustekinumab 
was a second-line treatment. First-line treatments included 
UVA/UVB light therapy, methotrexate (MTX), acitretin, and/
or cyclosporine A. Fumaric acid esters are not available in 
Switzerland. Ustekinumab was administered in the standard 
dosage (<100 kg: 45 mg, >100 kg: 90 mg; month 0, 1, 3).
Statistical analysis
HLA-Cw6 allele positive patients were compared to wild-
type patients for PASI 50, 75, 90, NAPSI, and DLQI at 16 
weeks after the onset of therapy. Statistical analysis was 
conducted with Student’s t-test using GraphPad Prism.
DNA extraction and genotyping
Genomic DNA was isolated from EDTA tubes with venous 
blood. A primer-specific polymerase chain reaction (Olerup 
SSP®, Vienna, Austria) was used for HLA-C*06 genotyping.
Results
Thirty patients were included in this retrospective study 
(Table 1), with almost three times as many men as women. 
At the onset, the average PASI was higher among HLA-Cw6+ 
patients, which was expected (11 vs. 8.6). The reduction in 
PASI 75 after 4 months was larger in the HLA-Cw6− partici-
pants (34.4%) as compared to HLA-Cw6+ patients (25.6%); 
however, this did not reach statistical significance (p=0.173). 
Table 1 Demographics, PASI, NAPSI, as well as DLQI
Patients All HLA-Cw6– HLA-Cw6+
Age, years* 49.6±12.1 (23–75) 50.3±12.1 (30–75) 48.6±12.5 (23–61)
Sex
Male 22 13 9
Female 8 4 4
PASI
Month 0* 9.6±4.9 (2–17.6) 8.6±3.4 (2–13.7) 11±6.3 (4.1–17.6)
Month 4* 3.3±5.4 (0–25.4) 2.2±2.1 (0–7.7) 6.5±15.2 (0–25.4)
PASI 50 23 13 10
PASI 75 13 9 5
PASI 90 10 5 3
Nail involvement 10/17 2/13
NAPSI
Month 0* 10.4 ±15.7 (0–60) 12.6 ±17.4 (0–60) 6.0±11.5 (0–30)
Month 4* 4.8±12.8 (0–60) 6.5±15.2 (0–60) 1.1±3.0 (0–8)
DLQI
Month 0* 11.5±6.4 (0–24) 11.5±6.2 (0–24) 12.6±7.0 (0–21)
Month 4* 3.5±5.0 (0–16) 4.0±4.8 (0–16) 2.6±5.5 (0–16)
Note: *Mean±SD (range).
Abbreviations: DLQI, Dermatology Life Quality Index; NAPSI, Nail Psoriasis Severity Index; PASI, Psoriasis Activity and Severity Index.
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PASI 50, 75, and 90 was achieved by 52.9%, 76.5%, and 
29.4% of patients in the HLA-Cw6− group, compared to 
76.9%, 38.5%, and 23.1% of patients in the HLA-Cw6+ 
group, respectively (Figure 1; Table 1). More patients with 
the HLA-Cw6+ allele had nail psoriasis (10/17), while in the 
other group, only two out of 13 showed nail involvement. The 
Nail Psoriasis Severity was higher among Cw6− patients; 
however, this could largely be due to the small sample size. 
The effect of ustekinumab between the groups showed no 
significant difference (p=0.374) regarding nail improvement 
(Figure 2). Life quality was similarly improved in both the 
HLA-Cw6− and Cw6+ patient groups (11.5–4.0 vs. 12.6–2.6, 
p=0.534; Figure 3).
Discussion
In this relatively small retrospective study, we observed a 
similar level of therapeutic response in psoriasis patients 
treated with ustekinumab regardless of their HLA-Cw6 sta-
tus. This is in contrast to the current literature that contains 
several publications indicating a superior treatment outcome 
in HLA-Cw6+ patients. A power analysis showed that the 
small cohort provided only little power (0.55 for PASI, 0.17 
for NAPSI, and 0.11 for DLQI) to detect any differences. In 
addition, the PASI at the start of ustekinumab therapy was 
on average 8.6 and 11.0, respectively, therefore rather low 
in comparison to other studies.
However, as we set out to investigate whether on a day-
to-day basis, the determination of the Cw6 allele may be of 
clinical utility or not, our data are relevant for the situation of 
making a treatment decision in a single patient. Even though 
in larger cohorts, a small signal for an additional therapeutic 
benefit of ustekinumab in Cw6+ patients was demonstrated, 
our findings suggest that Cw6 genotyping is probably of too 
limited value for routine integration into the clinical labora-
tory workup of moderate-to-severe patients.
It has to be emphasized that in the most recent study 
published by Li et al,9 the reported difference between 
 Cw6-positive and -negative groups was only moderate. This 
difference does not seem sufficient to guide clinical decisions 
or predictions based on the patient’s Cw6 genotype.
While several studies have previously shown a supe-
rior treatment response to ustekinumab in HLA-Cw6+ 
patients,9–13 the data concerning tumor necrosis factor-alpha 
Figure 1 PASI.
Notes: As previously reported, patients with HLA-Cw6+ had a higher PASI at the 
start, but it was not significantly reduced after 4 months compared to the control 
group of HLA-Cw6– patients.
Abbreviation: PASI, Psoriasis Activity and Severity Index.
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Figure 2 NAPSI.
Notes: The NAPSI even increased in the HLA-Cw6+ group, which is most likely 
due to the small number of participants, not to the ineffectiveness of secukinumab.
Abbreviation: NAPSI, Nail Psoriasis Severity Index.
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Figure 3 DLQI.
Notes: Life quality was better in both groups after 4 months of treatment. A larger 
decrease in DLQI was seen among patients in the HLA-Cw6+ group.
Abbreviation: DLQI, Dermatology Life Quality Index.
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antagonists and HLA-Cw6 were conflicting.15,16 In a study 
by Gonzalez-Lara et al, Cw6+ patients responded better 
to tumor necrosis factor-alpha antagonists as compared 
to Cw6− patients.16 A higher response rate of HLA-Cw6+ 
patients to MTX was seen in one study. Interestingly, 
HLA-Cw6 status (odds ratio: 2.75) was a more important 
predictor than even the dose of MTX (odds ratio: 1.08).17 
To date, no published studies have assessed the influence 
of HLA-Cw6 on secukinumab, ixekizumab, or apremilast 
therapy responses.
As personalized medicine is moving forward at a rapid 
pace, we are hard-pressed to find biomarkers to predict 
both therapeutic success and side effects of old and new 
drugs. HLA-Cw6 certainly is a candidate allele for such a 
need, but may on its own not mitigate the whole risk. In a 
previously published case report of homozygous twins, both 
positive for a HLA-Cw6 mutation, both of them responded 
well to ustekinumab therapy. Surprisingly, one of the twins 
was thereafter stable over time (PASI 5), while the other’s 
symptoms worsened (from PASI 9 to 33).18
Our study has the weakness of including only 30 patients. 
As it is a retrospective analysis and the genotyping was only 
done post hoc, observer bias is largely ruled out. It will be 
interesting to see further studies, especially on secukinumab, 
ixekizumab, or apremilast; but the quest for a gene aiding 
us in our choice of therapy and flawlessly predicting therapy 
outcome is not over yet.
Conclusion
In our opinion, routine HLA-Cw6 genotyping does not 
impact our clinical routine.
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